Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia


  • Kingsley Nnawuba Department of Internal Medicine, University of Arkansas for Medical Sciences, Northwest Regional Campus, Fayetteville, AR, United States
  • Ifeanyi Uche Department of Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, New York
  • Samantha Robinson Department of Mathematics, Fulbright College of Arts and Sciences, University of Arkansas, Fayetteville, AR, United States
  • Obed Asare Department of Information Systems, Walton College of Business, University of Arkansas, Fayetteville, AR, United States
  • Tochukwu Nzeako Department of Internal Medicine, Christiana Care Hospital, Newark, Delaware
  • Anup Kumar Trikannad Ashwini Kumar Division of Hematology Oncology and Myeloma, University of Arkansas for Medical Sciences, AR, United States
  • Hanna Jensen Department of Surgery, University of Arkansas for Medical Sciences, Northwest Regional Campus, Fayetteville, AR, United States



Hematological malignancies, Leukemia, Prolymphocytic leukemia, Cancer survival


Background: B-cell prolymphocytic leukemia (B-PLL) is a rare disease, consisting <1% of mature B-cell malignancies. B-PLL is often refractory to chemotherapy, with a median survival of 3 years. Due to its rarity, no large cohort studies exist elucidating outcomes.

Methods: All B-PLL patients >15 years were identified in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database between 2000-2020. Statistical analysis explored demographic variables like age; categorized as adolescent or young adult (AYA) and adults. In adults, differences in survival due to factors such as sex, race/ethnicity, household income, rurality, and age categorized in 10-15 year buckets was analyzed.

Results: B-PLL patients were predominantly white (78%), over 40 years (96%) and mostly residing in metropolitan areas (90%). Interestingly, the AYA cohort were mostly female (70%). 35% of the AYA patients were Hispanic, while being only 9% in adults. Among adults, the rate of Asian/Pacific-Islander patients that were alive at the time of the data query was 53% compared to 34% in Hispanic, 31% in black, and 24% in white patients (p=0.025). Younger age was also associated with greater chances of survival (p<0.001).

Conclusions: In line with known poor prognosis of the disease, 23% patients were alive at the time of data query. Female and Hispanic patients were overrepresented in the AYA age group. In the adult group Asian/Pacific-Islander patients had better survival outcomes, as did younger patients. Further research is necessary to explore why B-PLL incidence in AYA patients is higher among Hispanic and females.


van der Velden VH, Hoogeveen PG, de Ridder D, Schindler-van der Struijk M, van Zelm MC, Sanders M, et al. B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood. 2014;124(3):412-9.

Hercher C, Robain M, Davi F, Garand R, Flandrin G, Valensi F, et al. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma. 2001;42(5):981-7.

Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120(3):538-51.

Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control. 2008;19(4):379-90.

Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20-37.

Hothorn T, Hornik K, Zeileis A. Unbiased Recursive Partitioning: A Conditional Inference Framework. Journal of Computational and Graphical Statistics. 2006;15(3):651-74.

Ermann DA, Fitzgerald LA, Shah H, Hu B, Stephens DM. Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia. American Society of Hematology Annual Meeting; 2023; San Diego, CA: Blood; 2022. p. 6668-9.

Ionescu FAN, Khoury J, Gaikazian S, Stender M, Jaiyesimi I. Demographic and Survival in B-Cell Prolymphocytic Leukemia: An Analysis of SEER data. Lymphoma and Myeloma Congress; October 23-26; New York, NY: Journal of Hematology; 2019. p. S27-S8.

Miller KD, Ortiz AP, Pinheiro PS, Bandi P, Minihan A, Fuchs HE, et al. Cancer statistics for the US Hispanic/Latino population, 2021. CA Cancer J Clin. 2021;71(6):466-87.

Bencomo-Alvarez AE, Rubio AJ, Gonzalez MA, Eiring AM. Blood cancer health disparities in the United States Hispanic population. Cold Spring Harb Mol Case Stud. 2021;7(2).

Shvidel L, Shtalrid M, Bassous L, Klepfish A, Vorst E, Berrebi A. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma. 1999;33(1-2):169-79.




How to Cite

Nnawuba, K., Uche, I., Robinson, S., Asare, O., Nzeako, T., Trikannad Ashwini Kumar, A. K., & Jensen, H. (2024). Analyzing the incidence, survival, and demographic trends of B-cell prolymphocytic leukemia. International Journal Of Community Medicine And Public Health, 11(7), 2533–2539.



Original Research Articles